Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials

We analyzed pooled data from two comparable randomized placebo-controlled clinical trials of bupropion pharmacotherapy for smoking cessation for which data on DRD2 Taq1A genotype were available. A total of 722 smokers across the two trials were randomized to 10 weeks of sustained-release bupropion h...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: David, Sean P., Strong, David R., Munafò, Marcus R., Brown, Richard A., Lloyd-Richardson, Elizabeth E., Wileyto, Paul E., Evins, Eden A., Shields, Peter G., Lerman, Caryn, Niaura, Raymond
Format: Artigo
Jezik:Inglês
Izdano: 2007
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2128730/
https://ncbi.nlm.nih.gov/pubmed/18058343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14622200701705027
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items